All Stories

  1. Lupus Biomarker Discovery, Validation, Approval, and Impact on Clinical Trials

    Article • Current Treatment Options in Rheumatology, January 2015, Springer Science + Business Media

    Dr Joseph M Ahearn

  2. Antilymphocyte autoantibodies generate T cell–C4d signatures in systemic lupus erythematosus

    Article • Translational Research, December 2014, Elsevier

    Dr Joseph M Ahearn

  3. The Lupus Biomarker Odyssey: One Experience

    Article • January 2014, Springer Science + Business Media

    Dr Joseph M Ahearn

  4. Relation of Platelet C4d with All-Cause Mortality and Ischemic Stroke in Patients with Systemic Lupus Erythematosus

    Article • Translational Stroke Research, October 2013, Springer Science + Business Media

    Dr Joseph M Ahearn

  5. Cardiovascular disease in autoimmune rheumatic diseases

    Article • Autoimmunity Reviews, August 2013, Elsevier

    Dr Joseph M Ahearn

  6. Complement and SLE

    Article • January 2013, Elsevier

    Dr Joseph M Ahearn

  7. Complement fragment C3d is colocalized within the lipid rafts of T cells and promotes cytokine production

    Article • Lupus, July 2012, SAGE Publications

    Dr Joseph M Ahearn

  8. Biomarkers for systemic lupus erythematosus

    Article • Translational Research, April 2012, Elsevier

    Dr Joseph M Ahearn

  9. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study

    Article • Lupus, September 2011, SAGE Publications

    Dr Joseph M Ahearn

  10. Complement Proteins C3 and C4 Bind to Collagen and Elastin in the Vascular Wall: A Potential Role in Vascular Stiffness and Atherosclerosis

    Article • Clinical and Translational Science, June 2011, Wiley

    Dr Joseph M Ahearn

  11. Complement and Tissue Injury in SLE

    Article • January 2011, Elsevier

    Dr Joseph M Ahearn

  12. Complement C4d deposition on circulating blood cells: Mechanisms and implication in systemic lupus erythematosus (SLE)

    Article • Molecular Immunology, August 2010, Elsevier

    Dr Joseph M Ahearn

  13. Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients

    Article • The Journal of Heart and Lung Transplantation, April 2010, Elsevier

    Dr Joseph M Ahearn

  14. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus

    Article • Arthritis & Rheumatism, February 2010, Wiley

    Dr Joseph M Ahearn

  15. Cell-Bound Complement Biomarkers for Systemic Lupus Erythematosus: From Benchtop to Bedside

    Article • Rheumatic Disease Clinics of North America, February 2010, Elsevier

    Dr Joseph M Ahearn

  16. The search for lupus biomarkers

    Article • Best Practice & Research Clinical Rheumatology, August 2009, Elsevier

    Dr Joseph M Ahearn

  17. Lymphocyte‐Bound Complement Activation Products as Biomarkers for Diagnosis of Systemic Lupus Erythematosus

    Article • Clinical and Translational Science, August 2009, Wiley

    Dr Joseph M Ahearn

  18. A Model of Integrated Patient Care and Clinical Translational Research

    Article • Clinical and Translational Science, September 2008, Wiley

    Dr Joseph M Ahearn

  19. Faculty Opinions recommendation of The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

    Article • June 2008, F1000Research

    Dr Joseph M Ahearn

  20. Relative Contributions of Age and Atherosclerosis to Vascular Stiffness

    Article • Clinical and Translational Science, May 2008, Wiley

    Dr Joseph M Ahearn

  21. Faculty Opinions recommendation of Antielastin autoimmunity in tobacco smoking-induced emphysema.

    Article • January 2008, F1000Research

    Dr Joseph M Ahearn

  22. Anti-lymphocyte Autoantibodies in Systemic Lupus Erythematosus (SLE) Revisited

    Article • Clinical Immunology, January 2007, Elsevier

    Dr Joseph M Ahearn

  23. Complement C4d deposition on T lymphocytes: Mechanisms and significance in systemic lupus erythematosus (SLE)

    Article • Molecular Immunology, January 2007, Elsevier

    Dr Joseph M Ahearn

  24. PC4d, SLE, and cerebrovascular thrombosis

    Article • Molecular Immunology, January 2007, Elsevier

    Dr Joseph M Ahearn

  25. Platelet-associated C4 characterization and visualization: Clues to the vascular complications of lupus

    Article • Molecular Immunology, January 2007, Elsevier

    Dr Joseph M Ahearn

  26. Complement C4d Deposition on Circulating Blood Cells in Systemic Lupus Erythematosus (SLE)

    Article • Clinical Immunology, January 2007, Elsevier

    Dr Joseph M Ahearn

  27. EC4d and EC3d as biomarkers for monitoring disease activity in SLE

    Article • Molecular Immunology, January 2007, Elsevier

    Dr Joseph M Ahearn

  28. Faculty Opinions recommendation of Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.

    Article • October 2006, F1000Research

    Dr Joseph M Ahearn

  29. Apoptosis and autoimmunity

    Article • Immunologic Research, September 2006, Springer Science + Business Media

    Dr Joseph M Ahearn

  30. Platelet C4d is highly specific for systemic lupus erythematosus

    Article • Arthritis & Rheumatism, January 2006, Wiley

    Dr Joseph M Ahearn

  31. OR.63. T-Cells Bearing Complement Activation Products: SLE Biomarkers and Clues to Pathogenesis

    Article • Clinical Immunology, January 2006, Elsevier

    Dr Joseph M Ahearn

  32. F.26. Reticulocyte-Bound C4d As a Biomarker of Disease Activity in Patients with SLE

    Article • Clinical Immunology, January 2006, Elsevier

    Dr Joseph M Ahearn

  33. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus

    Article • Arthritis & Rheumatism, September 2005, Wiley

    Dr Joseph M Ahearn

  34. Biomarkers for systemic lupus erythematosus: a review and perspective

    Article • Current Opinion in Rheumatology, September 2005, Wolters Kluwer Health

    Dr Joseph M Ahearn

  35. Mining the complement system for lupus biomarkers

    Article • Clinical and Applied Immunology Reviews, May 2005, Elsevier

    Dr Joseph M Ahearn

  36. Acute-Phase Proteins and Inflammation: Immunological and Clinical Implications

    Article • January 2005, Elsevier

    Dr Joseph M Ahearn

  37. Complement in Health and Disease

    Article • January 2005, Elsevier

    Dr Joseph M Ahearn

  38. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus

    Article • Arthritis & Rheumatism, November 2004, Wiley

    Dr Joseph M Ahearn

  39. New advances in measurement of complement activation: Lessons of systemic lupus erythematosus

    Article • Current Rheumatology Reports, September 2004, Springer Science + Business Media

    Dr Joseph M Ahearn

  40. Complement as a source of biomarkers in systemic lupus erythematosus: Past, present, and future

    Article • Current Rheumatology Reports, April 2004, Springer Science + Business Media

    Dr Joseph M Ahearn

  41. Apoptosis and immune responses to self

    Article • Rheumatic Disease Clinics of North America, February 2004, Elsevier

    Dr Joseph M Ahearn

  42. Apoptosis of skeletal muscle cells and the pathogenesis of Myositis: A perspective

    Article • Current Rheumatology Reports, August 2001, Springer Science + Business Media

    Dr Joseph M Ahearn

  43. Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus

    Article • Current Rheumatology Reports, June 2001, Springer Science + Business Media

    Dr Joseph M Ahearn

  44. Role of Complement in Systemic Lupus Erythematosus Pathogenesis

    Article • January 2001, Elsevier

    Dr Joseph M Ahearn

  45. A hemagglutinin-C3d2 fusion protein protects mice from lethal infection with influenza virus

    Article • Immunopharmacology, August 2000, Elsevier

    Dr Joseph M Ahearn

  46. Apoptotic endothelial cells and PBMC are tagged specifically by C3-and C4-derived ligands during membrane loss of RCA proteins: Implications for immune tolerance and the pathogenesis of SLE

    Article • Immunopharmacology, August 2000, Elsevier

    Dr Joseph M Ahearn

  47. Ultraviolet B (UVB) induces apoptosis and deposition of C3- and C4-derived ligands on primary human and murine keratinocytes in vivo: Implications for immune tolerance and the pathogenesis of SLE

    Article • Immunopharmacology, August 2000, Elsevier

    Dr Joseph M Ahearn

  48. Apoptosis and autoimmunity: Complement deficiency and systemic lupus erythematosus revisited

    Article • Current Rheumatology Reports, February 2000, Springer Science + Business Media

    Dr Joseph M Ahearn

  49. The structural basis for complement receptor type 2 (CR2, CD21)-mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement-control protein-CR2 chimeras

    Article • European Journal of Immunology, December 1999, Wiley

    Dr Joseph M Ahearn

  50. The structural basis for complement receptor type 2 (CR2, CD21)-mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement-control protein-CR2 chimeras

    Article • European Journal of Immunology, December 1999, Wiley

    Dr Joseph M Ahearn

  51. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP)

    Article • Molecular Immunology, July 1999, Elsevier

    Dr Joseph M Ahearn

  52. Viral complement regulatory proteins

    Article • Immunopharmacology, May 1999, Elsevier

    Dr Joseph M Ahearn

  53. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance

    Article • Immunopharmacology, May 1999, Elsevier

    Dr Joseph M Ahearn

  54. Creation and functional characterization of spice, the small pox inhibitor of complement enzymes

    Article • Molecular Immunology, April 1998, Elsevier

    Dr Joseph M Ahearn

  55. The globular heads of C1q bind specifically to surface blebs of apoptotic human endothelial cells: Implications for immune tolerance

    Article • Molecular Immunology, April 1998, Elsevier

    Dr Joseph M Ahearn

  56. Complement Receptors

    Article • February 1998, Taylor & Francis

    Dr Joseph M Ahearn

  57. Disruption of the Cr2 Locus Results in a Reduction in B-1a Cells and in an Impaired B Cell Response to T-Dependent Antigen

    Article • Immunity, March 1996, Elsevier

    Dr Joseph M Ahearn

  58. CR1 and CR2: Receptors Mediating Cellular Recognition in the Complement System

    Article • January 1990, Elsevier

    Dr Joseph M Ahearn

  59. Structure and Function of the Complement Receptors, CR1 (CD35) and CR2 (CD21)

    Article • January 1989, Elsevier

    Dr Joseph M Ahearn

  60. Systemic Lupus Erythematosus

    Article • Medicine, September 1985, Wolters Kluwer Health

    Dr Joseph M Ahearn

  61. Relationships of hla‐dr and mt antigens to autoantibody expression in systemic lupus erythematosus

    Article • Arthritis & Rheumatism, December 1983, Wiley

    Dr Joseph M Ahearn

  62. Interrelationships of HLA‐DR, MB, AND MT phenotypes, autoantibody expression, and clinical features in systemic lupus erythematosus

    Article • Arthritis & Rheumatism, September 1982, Wiley

    Dr Joseph M Ahearn

  63. Cell-Bound Complement Activation Products (CB-CAPs) as a Source of Lupus Biomarkers

    Article • Springer Science + Business Media

    Dr Joseph M Ahearn